Xenon Pharmaceuticals (XENE) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 7, 2019 4:01 PM EDTCompany Reports Advancements in Neurology-Focused Pipeline and Anticipates Multiple Products in Phase 2 or Later Stage Development this Year
Conference Call at 4:30 pm ET Today
BURNABY, British Columbia, May 07, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2019 and provided a corporate update.
Dr. Simon Pimstone, Xenons Chief Executive Officer, said, We continue to make significant progress advancing our... More
